164 related articles for article (PubMed ID: 27527002)
1. Association of T Cell and Macrophage Activation with Arterial Vascular Health in HIV.
Grome HN; Barnett L; Hagar CC; Harrison DG; Kalams SA; Koethe JR
AIDS Res Hum Retroviruses; 2017 Feb; 33(2):181-186. PubMed ID: 27527002
[TBL] [Abstract][Full Text] [Related]
2. The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy.
Koethe JR; Grome H; Jenkins CA; Kalams SA; Sterling TR
AIDS; 2016 Jan; 30(1):83-91. PubMed ID: 26418084
[TBL] [Abstract][Full Text] [Related]
3. Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.
Calza L; Magistrelli E; Danese I; Colangeli V; Borderi M; Bon I; Re MC; Mancini R; Conti M; Motta R; Viale P
Curr HIV Res; 2016; 14(1):61-70. PubMed ID: 26531764
[TBL] [Abstract][Full Text] [Related]
4. HIV disease is associated with increased biomarkers of endothelial dysfunction despite viral suppression on long-term antiretroviral therapy in Botswana.
Mosepele M; Mohammed T; Mupfumi L; Moyo S; Bennett K; Lockman S; Hemphill LC; Triant VA
Cardiovasc J Afr; 2018 May/Jun 23; 29(3):155-161. PubMed ID: 29771268
[TBL] [Abstract][Full Text] [Related]
5. Endothelial activation and cardiometabolic profiles of treated and never-treated HIV infected Africans.
Fourie CM; Schutte AE; Smith W; Kruger A; van Rooyen JM
Atherosclerosis; 2015 May; 240(1):154-60. PubMed ID: 25795556
[TBL] [Abstract][Full Text] [Related]
6. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
Serrano-Villar S; Sainz T; Ma ZM; Utay NS; Chun TW; Mann S; Kashuba AD; Siewe B; Albanese A; Troia-Cancio P; Sinclair E; Somasunderam A; Yotter T; Deeks SG; Landay A; Pollard RB; Miller CJ; Moreno S; Asmuth DM
PLoS Pathog; 2016 Jan; 12(1):e1005381. PubMed ID: 26795282
[TBL] [Abstract][Full Text] [Related]
7. Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection.
Zanni MV; Toribio M; Robbins GK; Burdo TH; Lu MT; Ishai AE; Feldpausch MN; Martin A; Melbourne K; Triant VA; Suchindran S; Lee H; Hoffmann U; Williams KC; Tawakol A; Grinspoon SK
JAMA Cardiol; 2016 Jul; 1(4):474-80. PubMed ID: 27438325
[TBL] [Abstract][Full Text] [Related]
8. The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease.
Ho JE; Scherzer R; Hecht FM; Maka K; Selby V; Martin JN; Ganz P; Deeks SG; Hsue PY
AIDS; 2012 Jun; 26(9):1115-20. PubMed ID: 22382147
[TBL] [Abstract][Full Text] [Related]
9. HIV and cardiovascular diseases risk: exploring the interplay between T-cell activation, coagulation, monocyte subsets, and lipid subclass alterations.
Teer E; Joseph DE; Driescher N; Nell TA; Dominick L; Midgley N; Deshpande G; Page MJ; Pretorius E; Woudberg NJ; Lecour S; Glashoff RH; Essop MF
Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1146-H1157. PubMed ID: 30768357
[TBL] [Abstract][Full Text] [Related]
10. Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study.
Lake JE; Seang S; Kelesidis T; Liao DH; Hodis HN; Stein JH; Currier JS
HIV Clin Trials; 2015 Oct; 16(5):197-206. PubMed ID: 26360501
[TBL] [Abstract][Full Text] [Related]
11. Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: the IMMUNEF clinical trial.
Soria A; Trabattoni D; Squillace N; Rainone V; Gnudi F; Clerici M; Gori A; Bandera A
PLoS One; 2015; 10(2):e0117118. PubMed ID: 25671649
[TBL] [Abstract][Full Text] [Related]
12. Effect of didanosine, stavudine, and hydroxyurea therapy on apoptosis in CD45RA+ and CD45RO+ T lymphocyte subpopulations.
Nokta M; Rossero R; Nichols J; Rosenbaum M; Pollard RB
AIDS Res Hum Retroviruses; 1999 Feb; 15(3):255-64. PubMed ID: 10052756
[TBL] [Abstract][Full Text] [Related]
13. Lower Pre-Treatment T Cell Activation in Early- and Late-Onset Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome.
Goovaerts O; Jennes W; Massinga-Loembé M; Ondoa P; Ceulemans A; Vereecken C; Worodria W; Mayanja-Kizza H; Colebunders R; Kestens L;
PLoS One; 2015; 10(7):e0133924. PubMed ID: 26208109
[TBL] [Abstract][Full Text] [Related]
14. HIV infection, antiretroviral therapy, and measures of endothelial function, inflammation, metabolism, and oxidative stress.
Dysangco A; Liu Z; Stein JH; Dubé MP; Gupta SK
PLoS One; 2017; 12(8):e0183511. PubMed ID: 28817706
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
Naicker N; Naidoo A; Werner L; Garrett N; Majola N; Asari V; Baxter C; Grobler A; Karim QA; Karim SSA
Antivir Ther; 2017; 22(4):287-293. PubMed ID: 27835613
[TBL] [Abstract][Full Text] [Related]
16. Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.
Rudy BJ; Kapogiannis BG; Worrell C; Squires K; Bethel J; Li S; Wilson CM; Agwu A; Emmanuel P; Price G; Hudey S; Goodenow MM; Sleasman JW;
J Acquir Immune Defic Syndr; 2015 May; 69(1):52-60. PubMed ID: 25942459
[TBL] [Abstract][Full Text] [Related]
17. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
Gray CM; Schapiro JM; Winters MA; Merigan TC
AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.
Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH
Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220
[TBL] [Abstract][Full Text] [Related]
19. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V
J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625
[TBL] [Abstract][Full Text] [Related]
20. The effect of initiation of antiretroviral therapy on monocyte, endothelial and platelet function in HIV-1 infection.
O'Halloran JA; Dunne E; Gurwith M; Lambert JS; Sheehan GJ; Feeney ER; Pozniak A; Reiss P; Kenny D; Mallon P
HIV Med; 2015 Nov; 16(10):608-19. PubMed ID: 26111187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
